Howard SC, Jones DP, Pui C-H. The tumor lysis syndrome. N Engl J Med. 2011;364(19):1844–54. https://doi.org/10.1056/NEJMra0904569.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wilson FP, Berns JS. Tumor lysis syndrome: new challenges and recent advances. Adv Chronic Kidney Dis. 2014;21(1):18–26. https://doi.org/10.1053/j.ackd.2013.07.001.

Article  PubMed  PubMed Central  Google Scholar 

Tsokos GC, Balow JE, Spiegel RJ, Magrath IT. Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine (Baltimore). 1981;60(3):218–29. https://doi.org/10.1097/00005792-198105000-00005.

Article  CAS  PubMed  Google Scholar 

Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127(1):3–11. https://doi.org/10.1111/j.1365-2141.2004.05094.x.

Article  PubMed  Google Scholar 

Coiffier B, Altman A, Pui C-H, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol. 2008;26(16):2767–78. https://doi.org/10.1200/jco.2007.15.0177.

Article  CAS  PubMed  Google Scholar 

Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, et al. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol. 2015;26(10):2155–61. https://doi.org/10.1093/annonc/mdv317.

Article  CAS  PubMed  Google Scholar 

Chiang J, Chan A, Lian T, Tay K, Quek R, Tao M, et al. Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review. Asia Pac J Clin Oncol. 2011;7(4):351–6. https://doi.org/10.1111/j.1743-7563.2011.01464.x.

Article  PubMed  Google Scholar 

Jeha S, Kantarjian H, Irwin D, Shen V, Shenoy S, Blaney S, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek™), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2004;19(1):34–8. https://doi.org/10.1038/sj.leu.2403566.

Article  CAS  Google Scholar 

Feng X, Dong K, Pham D, Pence S, Inciardi J, Bhutada NS. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis. J Clin Pharm Ther. 2013;38(4):301–8. https://doi.org/10.1111/jcpt.12061.

Article  CAS  PubMed  Google Scholar 

Lopez-Olivo MA, Pratt G, Palla SL, Salahudeen A. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis. Am J Kidney Dis. 2013;62(3):481–92. https://doi.org/10.1053/j.ajkd.2013.02.378.

Article  CAS  PubMed  Google Scholar 

Darmon M, Guichard I, Vincent F. Rasburicase and tumor lysis syndrome: lower dosage, consideration of indications, and hyperhydration. J Clin Oncol. 2011;29(3):e67–8; author reply e9. https://doi.org/10.1200/jco.2010.32.6751.

Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J, et al. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone–results of a multicenter phase III study. J Clin Oncol. 2010;28(27):4207–13. https://doi.org/10.1200/jco.2009.26.8896.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin’s lymphoma. Am J Med. 1993;94(2):133–9. https://doi.org/10.1016/0002-9343(93)90174-n.

Article  CAS  PubMed  Google Scholar 

Wössmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A. Incidence of tumor lysis syndrome in children with advanced stage Burkitt’s lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol. 2003;82(3):160–5. https://doi.org/10.1007/s00277-003-0608-2.

Article  CAS  PubMed  Google Scholar 

Milligan DW, Grimwade D, Cullis JO, Bond L, Swirsky D, Craddock C, et al. Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol. 2006;135(4):450–74. https://doi.org/10.1111/j.1365-2141.2006.06314.x.

Article  CAS  PubMed  Google Scholar 

Montesinos P, Lorenzo I, Martín G, Sanz J, Pérez-Sirvent ML, Martínez D, et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica. 2008;93(1):67–74. https://doi.org/10.3324/haematol.11575.

Article  CAS  PubMed  Google Scholar 

Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 study. Blood. 2011;117(8):2358–65. https://doi.org/10.1182/blood-2010-03-273243.

Article  CAS  PubMed  Google Scholar 

Yamada K, Furusawa S, Saito K, Waga K, Koike T, Arimura H, et al. Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia. 1995;9(1):10–4.

CAS  PubMed  Google Scholar 

Cairo MS, Coiffier B, Reiter A, Younes A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010;149(4):578–86. https://doi.org/10.1111/j.1365-2141.2010.08143.x.

Article  CAS  PubMed  Google Scholar 

Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8. https://doi.org/10.1038/bmt.2012.244.

Article  CAS  PubMed  Google Scholar